Fred Hutch Preclinical Ultrasound

Fred Hutch 临床前超声

• 批准号: 10414698
• 负责人: Slobodan Beronja
• 金额: $ 37.31万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-15 至 2023-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10414698
• 关键词: Advanced Malignant Neoplasm; Animal Experimentation; Area; Automobile Driving; Books; Ensure; Evaluation; Fred Hutchinson Cancer Research Center; Funding; Grant; Human Resources; Image; Injections; Location; Logistics; Maintenance; Malignant Neoplasms; Morphologic artifacts; Oncology; Pacific Northwest; Pediatric Hospitals; Pre-Clinical Model; Principal Investigator; Research; Research Personnel; Resource Sharing; Rodent Model; Solid Neoplasm; System; Techniques; Time; Ultrasonography; United States National Institutes of Health; Universities; Washington; animal facility; anticancer research; bioimaging; catalyst; high standard; image visualization; imaging system; instrument; member; multidisciplinary; pre-clinical; pre-clinical research; preclinical imaging; research study; ultrasound; Advanced Malignant Neoplasm; Animal Experimentation; Area; Automobile Driving; Books; Ensure; Evaluation; Fred Hutchinson Cancer Research Center; Funding; Grant; Human Resources; Image; Injections; Location; Logistics; Maintenance; Malignant Neoplasms; Morphologic artifacts; Oncology; Pacific Northwest; Pediatric Hospitals; Pre-Clinical Model; Principal Investigator; Research; Research Personnel; Resource Sharing; Rodent Model; Solid Neoplasm; System; Techniques; Time; Ultrasonography; United States National Institutes of Health; Universities; Washington; animal facility; anticancer research; bioimaging; catalyst; high standard; image visualization; imaging system; instrument; member; multidisciplinary; pre-clinical; pre-clinical research; preclinical imaging; research study; ultrasound

PROJECT SUMMARY/ ABSTRACT This proposal is for a VisualSonics Vevo 3100 ultrasound unit to support preclinical small animal research at Fred Hutchinson Cancer Research Center (Fred Hutch), University of Washington (UW) and Seattle Children’s Hospital, all members of the NCI-designated Fred Hutch / UW Cancer Consortium. The new ultrasound system will be housed within the highly successful Fred Hutch Preclinical Imaging Shared Resource which is part of the Consortium’s overarching Translational BioImaging Core Shared Resource. Purchase of a Vevo 3100 Preclinical Imaging System will provide needed additional capacity and higher quality image visualization for oncology studies in rodent models. Ultrasound has become the preclinical standard for high- throughput evaluation of solid tumors in both orthotopic and heterotopic locations, and for precision percutaneous injection techniques necessary for preclinical cancer research. Currently, Fred Hutch Preclinical Imaging Shared Resource has a VisualSonics Vevo 2100 ultrasound imaging unit housed in a newly renovated ultrasound suite in the Small Animal Facility. This existing instrument supports at least nine users’ projects across three Fred Hutch Divisions and three multidisciplinary and/or multi-institutional Research Centers. These projects are funded through 13 NIH-sponsored grants and 6 non- NIH sponsored grants. The Vevo 2100 is also used by other shared resource groups, such as the Preclinical Model Core, to support additional NIH-funded research. Acquiring the Vevo 3100 Preclinical Imaging Ultrasound System would provide multiple benefits for researchers, including increased availability for imaging time and expanded research capabilities for advanced cancer studies through HD imaging and artifact reduction, superior to that of the Vevo 2100. The demand for the ultrasound machine is such that existing users find it difficult to book sufficient time for their research studies. The Principal Investigator, Dr. Sunil Hingorani, along with the Preclinical Imaging Shared Resource director and associated personnel, will support the use of this machine through his broad ultrasound expertise. Although there are other Vevo 3100 ultrasound systems in the Seattle area, these are unavailable to our users for a variety of logistical and research-related reasons. Through excellent institutional support, the Preclinical Imaging Shared Resource has continued to grow and will support this new instrument, ensuring high quality maintenance and oversight. The acquisition of the Vevo 3100 ultrasound will meet our growing demand and further serve as a catalyst for driving preclinical research in the Pacific Northwest region.

项目摘要/摘要 该建议是针对Visualsics Vevo 3100超声单元支持临床前小动物 华盛顿大学（UW）和 西雅图儿童医院，NCI指定的Fred Hutch / UW癌症财团的所有成员。新的 超声系统将安置在非常成功的Fred Hutch临床前成像共享资源中 这是该财团总体翻译生物成像核心共享资源的一部分。购买 VEVO 3100临床前成像系统将提供所需的额外容量和更高质量的图像 啮齿动物模型中肿瘤学研究的可视化。超声已成为高级临床前标准 原位和异位位置中实体瘤的吞吐量评估，并精确地评估 临床前癌研究所需的经皮注射技术。 目前，Fred Hutch临床前成像共享资源具有Visualsonics VEVO 2100超声波 在小型动物设施中，在新装修的超声套件中居住的成像单元。这种现有的仪器 在三个Fred Hutch部门和三个多学科和/或 多机构研究中心。这些项目是通过13个NIH赞助的赠款和6个非 - NIH赞助了赠款。 VEVO 2100也由其他共享资源组（例如临床前）使用 模型核心，以支持其他NIH资助的研究。获取VEVO 3100临床前成像 超声系统将为研究人员提供多种好处，包括增加成像的可用性 时间并扩大通过高清成像和人工制品的晚期癌症研究的研究能力 减少，优于VEVO 2100的降低。超声机的需求使得现有 用户发现很难为他们的研究预订足够的时间。首席研究员Sunil博士 Hingorani以及临床前成像共享资源总监和相关人员将支持 通过他广泛的超声专业知识，该机器的使用。虽然还有其他VEVO 3100超声波 西雅图地区的系统，我们的用户无法获得各种与后勤和研究有关的系统 原因。通过出色的机构支持，临床前成像共享资源继续进行 成长并将支持这种新工具，以确保高质量的维护和监督。收购 VEVO 3100超声将满足我们不断增长的需求，并进一步作为驱动临床前的催化剂 太平洋西北地区的研究。